Skip to main navigation Skip to search Skip to main content

Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
180 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys'. Together they form a unique fingerprint.
Sort by

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science